Molipaxin (Trazodone Hydrochloride)

Molipaxin (trazodone) acts on serotonergic pathways and is employed in the management of mood and sleep disorders.

• Major depressive disorder: alleviates depressive symptoms and improves mood in adult patients.
• Insomnia: promotes sleep onset and maintenance, reducing nighttime awakenings.
• Depressive symptoms associated with chronic illness: helps improve mood and quality of life when depression coexists with other medical conditions.

• Trazodone hydrochloride exerts its antidepressant effect by inhibiting the reuptake of serotonin, thereby increasing synaptic serotonin levels. It also antagonizes 5‑HT₂A receptors, which contributes to its anxiolytic and sleep‑promoting properties. Additional blockade of α₁‑adrenergic and histamine H₁ receptors accounts for its sedative and orthostatic effects. The combined serotonergic and receptor‑blocking actions modulate neuronal firing in limbic circuits, resulting in mood elevation and sedation.

Trazodone may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Dizziness: a sensation of light‑headedness or unsteadiness that may increase fall risk, especially when standing quickly.
• Dry mouth: reduced salivation leading to throat discomfort and increased thirst, often manageable with hydration.
• Drowsiness: pronounced sleepiness that can affect alertness and daily activities, particularly after the first doses.
• Nausea: mild to moderate stomach upset or queasiness, sometimes accompanied by loss of appetite.
• Headache: mild to moderate pain in the head, which may be intermittent or persistent.

Serious or Rare Side Effects

• Priapism: prolonged, painful erection lasting more than four hours, requiring urgent medical treatment to prevent tissue damage.
• Serotonin syndrome: a potentially life‑threatening condition marked by confusion, high fever, muscle rigidity, rapid heart rate, and tremor.
• Severe hypotension: a marked drop in blood pressure that can cause fainting, dizziness, and in extreme cases, shock.

When prescribing Molipaxin, clinicians should consider several precautionary measures to ensure patient safety.

• Assess cardiovascular status: monitor blood pressure and heart rate due to α₁‑adrenergic blockade.
• Avoid abrupt discontinuation: taper the dose under medical supervision to reduce withdrawal symptoms.
• Caution in hepatic impairment: dose adjustment may be required because of hepatic metabolism.
• Avoid concurrent MAO inhibitors: risk of serotonin syndrome if combined with MAO‑I therapy.
• Pregnancy and lactation: use only if potential benefits justify potential risks to the fetus or infant.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Trazodone can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid)

• MAO inhibitors: concurrent use can precipitate serotonin syndrome.
• Other serotonergic agents (SSRIs, SNRIs, triptans): increase risk of serotonin syndrome.
• Carbamazepine: induces metabolism, reducing trazodone plasma levels.
• Alcohol: enhances central nervous system depression and dizziness.

Moderate Interactions (Monitor Closely)

• Antihypertensives: additive hypotensive effect may require blood pressure monitoring.
• CNS depressants (benzodiazepines, opioids): may increase sedation and respiratory depression.
• CYP3A4 inhibitors (ketoconazole, erythromycin): may raise trazodone concentrations, adjust dose if needed.